Related Experiment Video
Updated: Nov 26, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients
Anwar M Hashem1,2, Abdullah Algaissi3,4, Sarah A Almahboub1
1Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Insights
Antibody responses, including neutralizing antibodies (nAbs), against SARS-CoV-2 proteins were detected in most COVID-19 patients. Higher antibody levels correlated with severe disease, ICU admission, and fatal outcomes, offering insights into COVID-19 severity.
Area of Science:
- Immunology
- Virology
- Infectious Diseases
Background:
- The Coronavirus Disease 2019 (COVID-19) pandemic, caused by SARS-CoV-2, presents significant global health challenges.
- Understanding antigen-specific immune responses is crucial for managing COVID-19 patients.
Purpose of the Study:
- To investigate the kinetics and neutralizing capabilities of IgM and IgG antibodies against SARS-CoV-2 spike (S) and nucleoproteins (N).
- To correlate antibody levels with COVID-19 disease severity, ICU admission, and patient outcomes.
Main Methods:
- Quantification of IgM and IgG antibodies targeting SARS-CoV-2 S and N proteins.
- Assessment of neutralizing antibody (nAb) levels.
- Correlation analysis of antibody titers with clinical presentation (mild, moderate, severe), ICU status, and survival.
Main Results:
- SARS-CoV-2 specific IgG, IgM, and nAbs were detectable in nearly all hospitalized COVID-19 patients.
- Patients with severe symptoms, ICU admission, or fatal outcomes exhibited significantly higher levels of nAbs and anti-S1/N IgG/IgM antibodies.
- Early anti-N antibody levels strongly correlated with disease severity.
Conclusions:
- Antibody responses, including neutralizing antibodies, are robust in COVID-19 patients and vary with disease severity.
- Anti-nucleoprotein antibody levels early in infection may serve as a marker for COVID-19 severity.
Abstract:
The Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2, continues to spread globally with significantly high morbidity and mortality rates. Antigen-specific responses are of unquestionable value for clinical management of COVID-19 patients. Here, we investigated the kinetics of IgM, IgG against the spike (S) and nucleoproteins (N) proteins and their neutralizing capabilities in hospitalized COVID-19 patients with different disease presentations (i.e., mild, moderate or severe), need for intensive care units (ICU) admission or outcomes (i.e., survival vs death). We show that SARS-CoV-2 specific IgG, IgM and neutralizing antibodies (nAbs) were readily detectable in almost all COVID-19 patients with various clinical presentations. Interestingly, significantly higher levels of nAbs as well as anti-S1 and -N IgG and IgM antibodies were found in patients with more severe symptoms, patients requiring admission to ICU or those with fatal outcomes. More importantly, early after symptoms onset, we found that the levels of anti-N antibodies correlated strongly with disease severity. Collectively, these findings provide new insights into the kinetics of antibody responses in COVID-19 patients with different disease severity.
More Related Videos
Related Concept Videos
01:36Humoral Immune Responses
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:23Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...